Search Results
Your search for ,New matches 16920 pages
Showing 1951 - 2000FDA Expands Pediatric Indication for Entrectinib and Approves New Pellet Formulation
On October 20, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the small-molecule tyrosine kinase inhibitor entrectinib (Rozlytrek) for pediatric patients aged 1 month and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion...
Pre- and Postsurgical Immunotherapy Improves Outcomes for Patients With Resectable Early-Stage NSCLC
Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival in patients with resectable early-stage non–small cell lung cancer (NSCLC). Results from the phase III CheckMate 77T study were presented at the ...
Is Idecabtagene Vicleucel Effective in Patients With Multiple Myeloma, Regardless of Race?
The chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel may offer an overall survival benefit in patients with multiple myeloma, regardless of their race or ethnicity, according to a novel study published by Peres et al in Blood Advances. Background Multiple myeloma—a cancer of...
Patients and Survivors of Cancer May Be Impacted by U.S. Drug Shortages
The drug shortage crisis in the United States may continue to impact the care of 10% of patients and survivors of cancer, according to a new survey from the American Cancer Society Cancer Action Network (ACS CAN). Survey Findings In the new survey, researchers asked 1,222 patients and survivors of...
Almost Half of Oncology Drugs Approved Since 1998 Have Been Precision Therapies, New Study Finds
Among the 198 new oncology drugs approved by the U.S. Food and Drug Administration (FDA) between 1998 and 2022, approximately 43% of them were precision therapies, according to a recent study published by Suehnholz et al in Cancer Discovery. Background Precision oncology therapies often require...
MRI Scans Could Predict Postradiation Urinary Side Effects in Patients With Prostate Cancer
Researchers have discovered that patients with longer prostatic urethras may have an increased risk of experiencing moderate and chronic urinary side effects after receiving radiation for prostate cancer, according to a recent study published by Lee et al in Academic Radiology. The new findings...
Air Pollution and Breast Cancer Risk: Residential and Workplace Exposure
Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas. Results of a study looking at the effects of both residential and workplace exposure to air pollution on breast cancer risk ...
Gut Microbiome Variations and Colorectal Cancer Risk
Researchers have identified significant variations in the gut microbiome of patients with precancerous colorectal lesions, suggesting a potential correlation between gut bacteria and the onset of precancerous lesions and colorectal cancer, according to new findings presented by Gacesa et al at...
The Future of AI in Cancer Care
New research has illustrated the strides being made to apply modern artificial intelligence (AI) computing methods to oncology, according to new findings to be presented at the European Society for Medical Oncology (ESMO) Congress 2023. Background Researchers have long investigated the potential of ...
Breast Cancer 2022–2023 Almanac
The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...
Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer
Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...
SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression
In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...
Expert Point of View: Virginia Kaklamani, MD
Virginia Kaklamani, MD, Professor of Medicine at the University of Texas (UT) Health Science Center San Antonio and leader of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, was enthusiastic about the results of the phase III CAPItello-291 trial. “The phase III...
Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results of...
T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
Expert Point of View: Seth Wander, MD, PhD
Seth Wander, MD, PhD, Assistant Professor, Mass General Cancer Center, Boston, commented on the findings of the EMERALD trial. “We have seen a large amount of new data emerging related to elacestrant and other novel SERDs [selective estrogen receptor degraders]. Despite initial expectations based...
EMERALD Trial: Elacestrant vs Standard Endocrine Monotherapy for Advanced Breast Cancer After CDK4/6 Inhibition
Elacestrant—an investigational oral selective estrogen receptor degrader (SERD)—achieved longer progression-free survival vs standard-of-care endocrine monotherapy as second- or third-line therapy in patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer in the ...
Expert Point of View: Nancy Chan, MD
Nancy Chan, MD, Director of Breast Cancer Clinical Research at NYU Langone’s Perlmutter Cancer Center, New York, commented on the monarchE analysis for The ASCO Post. She noted that the study investigated the addition of adjuvant abemaciclib (an oral CDK4/6 inhibitor) to endocrine therapy in a...
Update From monarchE: Benefit of Abemaciclib Increases Over Time in Early-Stage Breast Cancer
Results of a planned interim overall survival analysis of the phase III monarchE trial offered further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk disease, according to Stephen R.D....
PET Imaging May Validate Use of Antibody-Drug Conjugates Plus Lovastatin to Enhance HER2-Targeted Cancer Therapy
Monitored by immune positron-emission tomography (PET) imaging, a novel therapeutic approach combining HER2-targeted therapies with the lipid-lowering drug lovastatin may reduce the number of cancer treatments required to prevent tumor growth, according to a recent study published by Brown et al in ...
Tumor Debulking Plus Palliative Chemotherapy May Not Impact Quality of Life in Patients With Metastatic Colorectal Cancer
Intensive local-regional tumor debulking in addition to standard palliative chemotherapy may not impact the overall quality of life of patients with metastatic colorectal cancer, according to a novel study published by Bakkerus et al in JNCCN–Journal of the National Comprehensive Cancer Network....
FDA Approves Adjuvant Nivolumab for Stage IIB/IIC Melanoma
On October 13, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage IIB or IIC melanoma in patients aged 12 years and older. CheckMate 76K Efficacy was evaluated in CheckMate 76K (ClinicalTrials.gov identifier NCT04099251),...
ASCO Launches New Webinar: Making Palliative Care a Part of Your Oncology Practice
ASCO President Lynn Schuchter, MD, FASCO, has made access to palliative and supportive care among patients with cancer a central focus of her presidential term. Although not all cancer clinicians can be palliative care specialists, because palliative and supportive care are so essential to every...
Lung ART Trial: End of the Road for Postoperative Radiotherapy?
Lung cancer is a significant global health issue, remaining the leading cause of cancer-related deaths with 2.1 million new cases and 1.8 million deaths. Complete surgical resection is the treatment of choice for operable early-stage non–small cell lung cancer (NSCLC) and resectable stage IIIA...
Can AI Help Identify Kidney Tumors That May Respond to Immunotherapy?
Clear cell renal cell carcinoma is the most common type of kidney cancer, comprising 80% of all malignant tumors found within the kidney. Although some clear cell renal cell carcinoma tumors are sensitive to immune checkpoint inhibitors, currently, there are no measures to predict whether a tumor...
How War Has Disrupted the Management of Patients With Breast Cancer in Sudan
Sudan is the third-largest country in Africa, spanning 1,886,068 km2. It is situated in an area surrounded by North Africa, Sub-Saharan Africa, and the Middle East. As of 2020, Sudan had a population of approximately 43.8 million people, with a significant proportion being younger than age 15....
Patients With Cancer May Be Interested in Complementary Therapies, Survey Says
Researchers have found that patients and oncologists may be supportive of complementary therapies for cancer treatment, according to a new survey conducted on behalf of the Healing Works Foundation. However, the findings also indicated there may be a disconnect between the growing interest in...
Chemical Hair Relaxers May Increase Risk of Uterine Cancer Among Black Women
Researchers have found that long-term use of chemical hair relaxers may be associated with an increased risk of uterine cancer in postmenopausal Black women, according to a recent study published by Bertrand et al in Environmental Research. Background Chemical hair relaxers are heavily marketed to...
Nonmelanoma Skin Cancers May Have Higher Mortality Rate Than Melanoma
Nonmelanoma skin cancer may be causing a greater number of global deaths than melanoma, according to findings presented by Salah et al at the European Academy of Dermatology and Venerology Congress 2023. Investigators also suggested that nonmelanoma skin cancer may be underreported and that the...
IVIG May Reduce Infection Risk Among Patients With Multiple Myeloma Receiving Anti-BCMA Therapy
Although the 5-year survival rate for multiple myeloma has increased over the past 2 decades—from about 35% in 2000 to approximately 62% in 2015—due to more effective therapies, the cancer remains incurable. According to the American Cancer Society, this year, nearly 36,000 individuals will be...
Adjuvant Canakinumab in Completely Resected NSCLC
In the phase III CANOPY-A trial reported in Journal of Clinical Oncology, Edward B. Garon, MD, and colleagues found that adjuvant therapy with the interleukin (IL)-1β pathway inhibitor canakinumab did not significantly improve disease-free survival vs placebo in patients with completely resected...
Investigators Compare Health Information Exchange Data With Patient Self-Reported Data to Measure Cancer Screening Uptake
Investigators have determined that knowing which patient populations are following cancer screening guidelines may be beneficial to public health officials, policymakers, and researchers developing strategies to improve screening adherence, according to a recent study published by Bhattacharyya et...
Children of Young Female Patients With a History of Cancer May Be at Risk of Birth Defects
The children of adolescent and young adult female patients with a history of cancer may face a higher risk of birth defects, according to a recent study published by Murphy et al in Cancer Epidemiology, Biomarkers & Prevention. Background “Concerns like the health of future children are at the ...
Guideline Update Reflects Recent Surge of New Data in Systemic Therapy for Melanoma
A guideline update on systemic treatment for melanoma offers new guidance in several areas, including the selection of front-line therapy for patients with metastatic disease with and without BRAF mutations, treatment of patients with earlier-stage disease in the adjuvant setting, and emerging...
ASCO and State Affiliates Wrap Up Successful State Sessions
After a fast-paced first half of the year, most state legislatures across the 50 states and Washington, DC, have adjourned for the year. The Association for Clinical Oncology (ASCO) and State Affiliates successfully collaborated to advance many shared 2023 state advocacy priorities, including those ...
Expert Point of View: Gentry King, MD
Gentry King, MD, Assistant Professor in the Division of Hematology and Oncology, University of Washington, and Assistant Professor in the Clinical Research Division of Fred Hutchinson Cancer Center, Seattle, offered his thoughts on the findings of NuTide:121. “Only recently, with TOPAZ-1...
Tracking the Progress Being Made in the Treatment of Breast Cancer and the Challenges Ahead
Jame Abraham, MD, FACP, has been in the field of oncology for more than 2 decades, he and says this is both one of the most exhilarating and challenging times in cancer care. “What excites me the most are the innovations in treatment that are literally transforming the lives of our patients and...
Expert Point of View: Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, cautioned that although FLAURA2 is a positive result, most patients will still develop drug resistance. “The result is really good and clearly positive, but if you look at the survival curves, there is still early overlap in a way that makes it unlikely this combination will ...
FLAURA2 Trial: Osimertinib Plus Chemotherapy Improves Outcomes in Advanced EGFR-Positive NSCLC
First-line treatment with osimertinib plus platinum-based chemotherapy achieved a statistically significant and clinically meaningful progression-free survival improvement compared with osimertinib alone in patients with advanced epidermal growth factor receptor (EGFR)-mutated non–small cell lung...
Individualized SABR for Lung Tumors
In a phase II study (iSABR) reported in JAMA Oncology, Gensheimer et al found that individualized stereotactic ablative radiotherapy (SABR) for up to four lung cancer tumors was associated with a high degree of local control and the ability to minimize radiation doses. Study Details Two hundred and ...
Do Patients With Advanced Cancer Value Quality Over Quantity of Life?
A recent study published by Yong et al in Value in Health may help clarify the intricate interplay between the quality-of-life and survival preferences of patients with advanced cancer. Limited access to palliative care services may contribute to suffering, particularly among patients with cancer...
Adjuvant Pembrolizumab May Offer Survival Benefit Over Observation in Patients With Muscle-Invasive or Locally Advanced Urothelial Carcinoma
The Alliance Data and Safety Monitoring Board has determined that adjuvant pembrolizumab may improve disease-free survival in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma, according to the Alliance for Clinical Trials in Oncology. ...
Dendritic Cell Vaccine Plus Stem Cell Transplant for Multiple Myeloma
Although the development of new therapies for multiple myeloma has significantly improved response rates and outcomes for patients with the blood cancer, most patients eventually relapse, including those who initially achieved remission. A phase I study is investigating whether a dendritic cell...
Chemotherapy Shortages Ongoing, According to New Survey
The National Comprehensive Cancer Network® (NCCN®) has released a follow-up survey on the ongoing chemotherapy shortages, refreshing findings they originally shared in June 2023. According to their results, 72% of the cancer centers surveyed continue to experience a shortage of carboplatin, and 59% ...
Neighborhood Walkability and Risk of Obesity-Related Cancers
Residing in more walkable neighborhoods could protect against the risk of overall obesity-related cancers in female patients, according to a recent study published by India-Aldana et al in Environmental Health Perspectives. Background Obesity has previously been linked to an increased risk of...
A Diagnosis of Ewing Sarcoma Altered the Trajectory of My Life
In August 2014, just a few weeks after my 15th birthday, my body began sending me a lot of worrisome signals that life as I knew it would soon be over. The year before, I had developed a hematoma in my right femur, which was resolved with surgery. But now the pain I was experiencing in that leg was ...
Psilocybin
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...
Structural Racism’s Effect on Cancer Mortality Rates
Racial minority patients are impacted differently by the social and physical characteristics of their environments, which may negatively affect cancer outcomes compared with White patients with cancer, according to a new study by Robinson-Oghogho et al presented during the 16th AACR Conference on...
National Inventors Hall of Fame Recognizes Jennifer Doudna, PhD; Emmanuelle Charpentier, PhD; and Angela Hartley Brodie, PhD
The National Inventors Hall of Fame (NIHF) recognizes the enduring legacies of exceptional U.S. patent holders on an annual basis. On October 26, 2023, three female inductees will be recognized for their extraordinary contributions to cancer care and clinical research. Biochemist Jennifer...
